Hepatokine leukocyte cell‐derived chemotaxin 2 as a biomarker of insulin resistance, liver enzymes, and metabolic dysfunction‐associated steatotic liver disease in the general population
ABSTRACT Aims/Introduction Leukocyte cell‐derived chemotaxin 2 (LECT2) is an obesity‐associated hepatokine that causes skeletal muscle insulin resistance. Since LECT2 is up‐regulated by the inactivation of the energy sensor AMPK in the liver, we hypothesized that LECT2 has potential as a biomarker f...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-02-01
|
| Series: | Journal of Diabetes Investigation |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/jdi.14351 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832574999370661888 |
|---|---|
| author | Keita Suzuki Hiromasa Tsujiguchi Akinori Hara Yumie Takeshita Hisanori Goto Yujiro Nakano Reina Yamamoto Hiroaki Takayama Atsushi Tajima Tatsuya Yamashita Masao Honda Hiroyuki Nakamura Toshinari Takamura |
| author_facet | Keita Suzuki Hiromasa Tsujiguchi Akinori Hara Yumie Takeshita Hisanori Goto Yujiro Nakano Reina Yamamoto Hiroaki Takayama Atsushi Tajima Tatsuya Yamashita Masao Honda Hiroyuki Nakamura Toshinari Takamura |
| author_sort | Keita Suzuki |
| collection | DOAJ |
| description | ABSTRACT Aims/Introduction Leukocyte cell‐derived chemotaxin 2 (LECT2) is an obesity‐associated hepatokine that causes skeletal muscle insulin resistance. Since LECT2 is up‐regulated by the inactivation of the energy sensor AMPK in the liver, we hypothesized that LECT2 has potential as a biomarker for metabolic dysfunction‐associated steatotic liver disease (MASLD). Therefore, we investigated whether circulating LECT2 levels are associated with insulin sensitivity, liver enzymes, and MASLD. Materials and Methods This cross‐sectional study included 138 Japanese individuals. Plasma LECT2 levels were measured using fasting blood samples. B‐mode ultrasonography was used to assess hepatic steatosis. Results The mean age and body mass index (BMI) of participants were 63.5 ± 10.2 years and 23.0 ± 3.1 kg/m2, respectively. Higher LECT2 levels positively correlated with homeostatic model assessment for insulin resistance (HOMA‐IR) values and negatively correlated with the quantitative insulin sensitivity check index (QUICKI) among all participants (HOMA‐IR; non‐standardized β (B) = 6.38, P < 0.01: QUICKI; B = −161, P < 0.01). These correlations were stronger in the low BMI group (HOMA‐IR; B = 13.85, P < 0.01: QUICKI; B = −180, P < 0.01). LECT2 levels also positively correlated with gamma‐glutamyl transferase levels (B = 0.01, P = 0.01) and alanine aminotransferase levels (B = 0.33, P = 0.02). Higher LECT2 levels correlated with the prevalence of MASLD (odds ratio = 1.14, P = 0.02). Conclusions The present results suggest the potential of plasma LECT2 levels as a biomarker for insulin resistance in individuals who are not overweight and the prevalence of MASLD in the general population. |
| format | Article |
| id | doaj-art-27f6288c3c2e409fafc912f719179bf2 |
| institution | Kabale University |
| issn | 2040-1116 2040-1124 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Investigation |
| spelling | doaj-art-27f6288c3c2e409fafc912f719179bf22025-02-01T10:02:01ZengWileyJournal of Diabetes Investigation2040-11162040-11242025-02-0116229830810.1111/jdi.14351Hepatokine leukocyte cell‐derived chemotaxin 2 as a biomarker of insulin resistance, liver enzymes, and metabolic dysfunction‐associated steatotic liver disease in the general populationKeita Suzuki0Hiromasa Tsujiguchi1Akinori Hara2Yumie Takeshita3Hisanori Goto4Yujiro Nakano5Reina Yamamoto6Hiroaki Takayama7Atsushi Tajima8Tatsuya Yamashita9Masao Honda10Hiroyuki Nakamura11Toshinari Takamura12Kanazawa University Advanced Preventive Medical Sciences Research Center Kanazawa Ishikawa JapanKanazawa University Advanced Preventive Medical Sciences Research Center Kanazawa Ishikawa JapanKanazawa University Advanced Preventive Medical Sciences Research Center Kanazawa Ishikawa JapanDepartment of Endocrinology and Metabolism Kanazawa University Graduate School of Medical Sciences Kanazawa Ishikawa JapanDepartment of Endocrinology and Metabolism Kanazawa University Graduate School of Medical Sciences Kanazawa Ishikawa JapanDepartment of Endocrinology and Metabolism Kanazawa University Graduate School of Medical Sciences Kanazawa Ishikawa JapanDepartment of Endocrinology and Metabolism Kanazawa University Graduate School of Medical Sciences Kanazawa Ishikawa JapanDepartment of Endocrinology and Metabolism Kanazawa University Graduate School of Medical Sciences Kanazawa Ishikawa JapanKanazawa University Advanced Preventive Medical Sciences Research Center Kanazawa Ishikawa JapanDepartment of Gastroenterology Kanazawa University Graduate School of Medical Sciences Kanazawa Ishikawa JapanDepartment of Gastroenterology Kanazawa University Graduate School of Medical Sciences Kanazawa Ishikawa JapanKanazawa University Advanced Preventive Medical Sciences Research Center Kanazawa Ishikawa JapanDepartment of Endocrinology and Metabolism Kanazawa University Graduate School of Medical Sciences Kanazawa Ishikawa JapanABSTRACT Aims/Introduction Leukocyte cell‐derived chemotaxin 2 (LECT2) is an obesity‐associated hepatokine that causes skeletal muscle insulin resistance. Since LECT2 is up‐regulated by the inactivation of the energy sensor AMPK in the liver, we hypothesized that LECT2 has potential as a biomarker for metabolic dysfunction‐associated steatotic liver disease (MASLD). Therefore, we investigated whether circulating LECT2 levels are associated with insulin sensitivity, liver enzymes, and MASLD. Materials and Methods This cross‐sectional study included 138 Japanese individuals. Plasma LECT2 levels were measured using fasting blood samples. B‐mode ultrasonography was used to assess hepatic steatosis. Results The mean age and body mass index (BMI) of participants were 63.5 ± 10.2 years and 23.0 ± 3.1 kg/m2, respectively. Higher LECT2 levels positively correlated with homeostatic model assessment for insulin resistance (HOMA‐IR) values and negatively correlated with the quantitative insulin sensitivity check index (QUICKI) among all participants (HOMA‐IR; non‐standardized β (B) = 6.38, P < 0.01: QUICKI; B = −161, P < 0.01). These correlations were stronger in the low BMI group (HOMA‐IR; B = 13.85, P < 0.01: QUICKI; B = −180, P < 0.01). LECT2 levels also positively correlated with gamma‐glutamyl transferase levels (B = 0.01, P = 0.01) and alanine aminotransferase levels (B = 0.33, P = 0.02). Higher LECT2 levels correlated with the prevalence of MASLD (odds ratio = 1.14, P = 0.02). Conclusions The present results suggest the potential of plasma LECT2 levels as a biomarker for insulin resistance in individuals who are not overweight and the prevalence of MASLD in the general population.https://doi.org/10.1111/jdi.14351Insulin resistanceLECT2MASLD |
| spellingShingle | Keita Suzuki Hiromasa Tsujiguchi Akinori Hara Yumie Takeshita Hisanori Goto Yujiro Nakano Reina Yamamoto Hiroaki Takayama Atsushi Tajima Tatsuya Yamashita Masao Honda Hiroyuki Nakamura Toshinari Takamura Hepatokine leukocyte cell‐derived chemotaxin 2 as a biomarker of insulin resistance, liver enzymes, and metabolic dysfunction‐associated steatotic liver disease in the general population Journal of Diabetes Investigation Insulin resistance LECT2 MASLD |
| title | Hepatokine leukocyte cell‐derived chemotaxin 2 as a biomarker of insulin resistance, liver enzymes, and metabolic dysfunction‐associated steatotic liver disease in the general population |
| title_full | Hepatokine leukocyte cell‐derived chemotaxin 2 as a biomarker of insulin resistance, liver enzymes, and metabolic dysfunction‐associated steatotic liver disease in the general population |
| title_fullStr | Hepatokine leukocyte cell‐derived chemotaxin 2 as a biomarker of insulin resistance, liver enzymes, and metabolic dysfunction‐associated steatotic liver disease in the general population |
| title_full_unstemmed | Hepatokine leukocyte cell‐derived chemotaxin 2 as a biomarker of insulin resistance, liver enzymes, and metabolic dysfunction‐associated steatotic liver disease in the general population |
| title_short | Hepatokine leukocyte cell‐derived chemotaxin 2 as a biomarker of insulin resistance, liver enzymes, and metabolic dysfunction‐associated steatotic liver disease in the general population |
| title_sort | hepatokine leukocyte cell derived chemotaxin 2 as a biomarker of insulin resistance liver enzymes and metabolic dysfunction associated steatotic liver disease in the general population |
| topic | Insulin resistance LECT2 MASLD |
| url | https://doi.org/10.1111/jdi.14351 |
| work_keys_str_mv | AT keitasuzuki hepatokineleukocytecellderivedchemotaxin2asabiomarkerofinsulinresistanceliverenzymesandmetabolicdysfunctionassociatedsteatoticliverdiseaseinthegeneralpopulation AT hiromasatsujiguchi hepatokineleukocytecellderivedchemotaxin2asabiomarkerofinsulinresistanceliverenzymesandmetabolicdysfunctionassociatedsteatoticliverdiseaseinthegeneralpopulation AT akinorihara hepatokineleukocytecellderivedchemotaxin2asabiomarkerofinsulinresistanceliverenzymesandmetabolicdysfunctionassociatedsteatoticliverdiseaseinthegeneralpopulation AT yumietakeshita hepatokineleukocytecellderivedchemotaxin2asabiomarkerofinsulinresistanceliverenzymesandmetabolicdysfunctionassociatedsteatoticliverdiseaseinthegeneralpopulation AT hisanorigoto hepatokineleukocytecellderivedchemotaxin2asabiomarkerofinsulinresistanceliverenzymesandmetabolicdysfunctionassociatedsteatoticliverdiseaseinthegeneralpopulation AT yujironakano hepatokineleukocytecellderivedchemotaxin2asabiomarkerofinsulinresistanceliverenzymesandmetabolicdysfunctionassociatedsteatoticliverdiseaseinthegeneralpopulation AT reinayamamoto hepatokineleukocytecellderivedchemotaxin2asabiomarkerofinsulinresistanceliverenzymesandmetabolicdysfunctionassociatedsteatoticliverdiseaseinthegeneralpopulation AT hiroakitakayama hepatokineleukocytecellderivedchemotaxin2asabiomarkerofinsulinresistanceliverenzymesandmetabolicdysfunctionassociatedsteatoticliverdiseaseinthegeneralpopulation AT atsushitajima hepatokineleukocytecellderivedchemotaxin2asabiomarkerofinsulinresistanceliverenzymesandmetabolicdysfunctionassociatedsteatoticliverdiseaseinthegeneralpopulation AT tatsuyayamashita hepatokineleukocytecellderivedchemotaxin2asabiomarkerofinsulinresistanceliverenzymesandmetabolicdysfunctionassociatedsteatoticliverdiseaseinthegeneralpopulation AT masaohonda hepatokineleukocytecellderivedchemotaxin2asabiomarkerofinsulinresistanceliverenzymesandmetabolicdysfunctionassociatedsteatoticliverdiseaseinthegeneralpopulation AT hiroyukinakamura hepatokineleukocytecellderivedchemotaxin2asabiomarkerofinsulinresistanceliverenzymesandmetabolicdysfunctionassociatedsteatoticliverdiseaseinthegeneralpopulation AT toshinaritakamura hepatokineleukocytecellderivedchemotaxin2asabiomarkerofinsulinresistanceliverenzymesandmetabolicdysfunctionassociatedsteatoticliverdiseaseinthegeneralpopulation |